RECEIVED
CENTRAL FAX CENTER
MAR 2 0 2007

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) An orally disintegrable tablet which comprises

(i) fine granules having an average particle diameter of 400 μm or less, which fine granules comprise: (a) a first composition ~~coated by an enteric coating layer comprising a first component which is an enteric coating agent and a second component which is a sustained release agent, said composition~~ having 10 weight % or more of an acid-labile physiologically active substance, (b) an enteric coating layer for the first composition comprising a first component that is an enteric coating agent and a second component that is a sustained released agent, and (c) ~~wherein the composition coated by an enteric coating layer is further coated by~~ a coating layer comprising mannitol outside the enteric coating layer ~~which comprises a water-soluble sugar alcohol~~; and

(ii) a water-soluble sugar alcohol, wherein said water-soluble sugar alcohol is comprised in the tablet separately from said fine granules (i) in said tablet and wherein the water-soluble sugar alcohol separate from said fine granules is in an amount of 5 to 97 weight % relative to 100 weight % of the orally disintegrable tablet apart from the fine granules;

wherein said tablet having a hardness strength of about 1 to about 20 kg is orally

PAGE 3/9 * RCVD AT 3/20/2007 3:39:42 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/33 * DNIS:2738300 * CSID:612-455-3801 * DURATION (mm-ss):01-30

disintegrable;

and wherein the oral disintegration time for complete disintegration of said tablet is one minute or less.

2. (Original) An orally disintegrable tablet of claim 1, wherein the average particle diameter of the fine granules is 300 to 400 μm.

3. (Original) An orally disintegrable tablet of claim 1, wherein the fine granules further comprise a basic inorganic salt.

4-6. (Cancelled)

7. (Original) An orally disintegrable tablet of claim 1, wherein the particle diameter of the fine granules is practically 425 μm or less.

8. (Cancelled)

9. (Original) An orally disintegrable tablet of claim 1, wherein the acid-labile physiologically active substance is a benzimidazole compound or a salt thereof.

10. (Cancelled)

11. (Original) An orally disintegrable tablet of claim 3, wherein the basic inorganic

PAGE 4/9 * RCVD AT 3/20/2007 3:39:42 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/33 * DNIS:2738300 * CSID:612-455-3801 * DURATION (mm-ss):01-30

salt is a salt of magnesium and/or a salt of calcium.

12. (Currently Amended) An orally disintegrable tablet of claim 1, wherein the first composition comprises a core being coated by a benzimidazole compound and a basic inorganic salt, said core comprising crystalline cellulose and lactose.

13. (Original) An orally disintegrable tablet of claim 12, wherein the core comprises 50 weight % or more of lactose.

14. (Original) An orally disintegrable tablet of claim 12, wherein the core comprises 40 to 50 weight % of crystalline cellulose and 50 to 60 weight % of lactose.

15. (Currently Amended) An orally disintegrable tablet of claim 1, wherein the first composition comprises 20 weight % or more of an acid-labile physiologically active substance.

16. (Currently Amended) An orally disintegrable tablet of claim 1, wherein the first composition comprises 20 to 50 weight % of an acid-labile physiologically active substance.

17. (Original) An orally disintegrable tablet of claim 1, wherein the fine granules are produced by fluidized-bed granulation method.

18. (Original) An orally disintegrable tablet of claim 1, wherein the enteric coating layer comprises an aqueous enteric polymer agent.

PAGE 5/9 * RCVD AT 3/20/2007 3:39:42 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/33 * DNIS:2738300 * CSID:612-455-3801 * DURATION (mm-ss):01-30

19. (Original) An orally disintegrable tablet of claim 18, wherein the aqueous enteric polymer agent is a methacrylate copolymer.

20. (Cancelled)

21. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the sustained-release agent is a methacrylate copolymer.

22. (Previously Presented) An orally disintegrable tablet of claim 18, wherein the sustained-release agent is in an amount of 5 to 15 weight % relative to 100 weight % of the aqueous enteric polymer agent.

23. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the water-soluble sugar alcohol in (ii) is erythritol.

24. (Previously Presented) An orally disintegrable tablet of claim 1, wherein the water-soluble sugar alcohol in (ii) is mannitol.

25-28. (Cancelled)

29. (Original) An orally disintegrable tablet of claim 1, which further comprises crospovidone.

PAGE 6/9 * RCVD AT 3/20/2007 3:39:42 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/33 * DNIS:2738300 * CSID:612-455-3801 * DURATION (mm-ss):01-30

30. (Cancelled)

31. (Original) An orally disintegrable tablet of claim 1, which comprises no lubricant inside the tablet.

32-49. (Cancelled)

50. (Previously Presented) An orally disintegrable tablet of claim 1, wherein an additive selected from crystalline cellulose, low substituted hydroxypropyl cellulose or a combination thereof is further comprised in combination with said water-soluble sugar alcohol in (ii).

51. (Previously Presented) An orally disintegrable tablet of claim 50, wherein the crystalline cellulose is in an amount of 3 to 50 weight % relative to 100 weight % of the tablet apart from the fine granule.

52-53. (Cancelled)

54. (New) An orally disintegrable tablet of claim 9, wherein the benzimidazole compound is lansoprazole.

PAGE 7/9 * RCVD AT 3/20/2007 3:39:42 PM [Eastern Daylight Time] * SVR:USPTO-EFXRF-6/33 * DNIS:2738300 * CSID:612-455-3801 * DURATION (mm-ss):01-30